Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects-Reference-Cited by-同舟云学术

Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects

Published:2019 Issue:33 Volume:17 Page:7760-7771
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Zhao Lei¹²³,Wang Baohua¹²³,Wang Limin¹²³,Zhao Xie⁴⁵⁶³,Chen Zhe⁷²³,Sun Lixia¹²³^ORCID

Affiliation:

1. North China University of Science and Technology Affiliated Hospital

2. Tangshan

3. P.R. China

4. Peking University

5. College of Pharmaceutical Sciences

6. Beijing

7. North China University of Science and Technology

Abstract

Schematic diagram of the discovery, design, screening and evaluation of a fully novel OXM derivative.

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/OB/C9OB01132C

Reference34 articles.

1. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management

2. Diagnosis and Classification of Diabetes Mellitus

3. Distribution of Oxyntomodulin and Glucagon in the Gastrointestinal Tract and the Plasma of the Rat*

4. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.

5. Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy;Science China Life Sciences;2023-04-21

2. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity;Peptides;2023-04

3. Fatty acid chain modification of loxenatide and its kinetics in a continuous flow microchannel reactor;Process Biochemistry;2023-01

4. Recycling reaction and separation for FACylation of loxenatide by trade-off between miscibility and immiscibility of reactants and product in methanol solution;Journal of Chromatography A;2022-08

5. I-M-150847, a novel GLP-1 and GIP receptor dual agonist, reduces body weight gain and improves glycemic control in the rodent model of type 2 diabetes and obesity;2021-12-09